Earnings Preview: Kura Oncology

Kura Oncology (NASDAQ:KURA) is set to give its latest quarterly earnings report on Wednesday, 2022-08-03. Here's what investors need to know before the announcement. Analysts estimate that Kura Oncology will report an earnings per share (EPS) of $-0.52.

Kura Oncology (NASDAQ:KURA) is set to give its latest quarterly earnings report on Wednesday, 2022-08-03. Here’s what investors need to know before the announcement.

Analysts estimate that Kura Oncology will report an earnings per share (EPS) of $-0.52.

Kura Oncology bulls will hope to hear the company to announce they’ve not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.

New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).

Past Earnings Performance

Last quarter the company beat EPS by $0.03, which was followed by a 10.58% drop in the share price the next day.

Here’s a look at Kura Oncology’s past performance and the resulting price change:

 

Quarter Q1 2022 Q4 2021 Q3 2021 Q2 2021
EPS Estimate -0.52 -0.53 -0.54 -0.49
EPS Actual -0.49 -0.49 -0.50 -0.51
Price Change % -10.58% 10.56% 8.36% -3.17%

eps graph

Stock Performance

Shares of Kura Oncology were trading at $14.93 as of August 01. Over the last 52-week period, shares are down 15.4%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release.

To track all earnings releases for Kura Oncology visit their earnings calendar on our site.

This article was generated by Benzinga’s automated content engine and reviewed by an editor.

Total
0
Shares
Related Posts
Read More

The Trade Desk Stock Climbs After Mixed Q4 Results, Expanded Share Repurchase

The Trade Desk reported quarterly earnings of 41 cents per share which missed the analyst consensus estimate of 43 cents by 4.65%. The company reported quarterly sales of $605.8 million, beating the analyst consensus estimate of $582.17 million by 4.06% and representing a 23.45% increase over sales of $490.74 million from the same period last year.

TTD